204 related articles for article (PubMed ID: 25703610)
1. Post-Injection Delirium/Sedation Syndrome after Olanzapine Long-Acting Intramuscular Injection - Who is at Risk?
Łukasik-Głębocka M; Sommerfeld K; Teżyk A; Panieński P; Żaba C; Zielińska-Psuja B
Basic Clin Pharmacol Toxicol; 2015 Sep; 117(3):213-4. PubMed ID: 25703610
[TBL] [Abstract][Full Text] [Related]
2. Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice.
Bushe CJ; Falk D; Anand E; Casillas M; Perrin E; Chhabra-Khanna R; Detke HC
BMC Psychiatry; 2015 Apr; 15():65. PubMed ID: 25886006
[TBL] [Abstract][Full Text] [Related]
3. [Post-injection delirium/sedation syndrome following injection of olanzapine pamoate: a new syndrome in emergency psychiatry].
Buts K; Van Hecke J
Tijdschr Psychiatr; 2014; 56(4):273-6. PubMed ID: 24807388
[TBL] [Abstract][Full Text] [Related]
4. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases.
Detke HC; McDonnell DP; Brunner E; Zhao F; Sorsaburu S; Stefaniak VJ; Corya SA
BMC Psychiatry; 2010 Jun; 10():43. PubMed ID: 20537128
[TBL] [Abstract][Full Text] [Related]
5. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism.
McDonnell DP; Detke HC; Bergstrom RF; Kothare P; Johnson J; Stickelmeyer M; Sanchez-Felix MV; Sorsaburu S; Mitchell MI
BMC Psychiatry; 2010 Jun; 10():45. PubMed ID: 20537130
[TBL] [Abstract][Full Text] [Related]
6. Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS).
Novakovic V; Adel T; Peselow E; Lindenmayer JP
Clin Neuropharmacol; 2013; 36(2):59-62. PubMed ID: 23503549
[TBL] [Abstract][Full Text] [Related]
7. Occurrence of post-injection delirium/sedation syndrome after application of olanzapine long-acting injection during one year period.
Uzun S; Kozumplik O; Ćelić I; Pivac N; Mimica N
Psychiatr Danub; 2017 Dec; 29(4):497-499. PubMed ID: 29197208
[TBL] [Abstract][Full Text] [Related]
8. Olanzapine pamoate for the treatment of schizophrenia--a safety evaluation.
Samalin L; Garay R; Ameg A; Llorca PM
Expert Opin Drug Saf; 2016; 15(3):403-11. PubMed ID: 26761429
[TBL] [Abstract][Full Text] [Related]
9. Olanzapine pamoate for the treatment of schizophrenia.
Naber D
Expert Opin Pharmacother; 2011 Mar; 12(4):627-33. PubMed ID: 21254860
[TBL] [Abstract][Full Text] [Related]
10. Olanzapine: a review of rapid and long-acting parenteral formulations.
Owen RT
Drugs Today (Barc); 2010 Mar; 46(3):173-81. PubMed ID: 20467591
[TBL] [Abstract][Full Text] [Related]
11. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.
Kane JM; Detke HC; Naber D; Sethuraman G; Lin DY; Bergstrom RF; McDonnell D
Am J Psychiatry; 2010 Feb; 167(2):181-9. PubMed ID: 20008947
[TBL] [Abstract][Full Text] [Related]
12. Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study.
Jones ME; Andrews JS; Faries DE; Landry J; Xu J; Detke HC; Chhabra-Khanna R; McDonnell DP
BMC Psychiatry; 2015 Nov; 15():278. PubMed ID: 26567159
[TBL] [Abstract][Full Text] [Related]
13. [A case of delirium after olanzapine intoxication].
Steil B
Nervenarzt; 2003 Nov; 74(11):1009-11. PubMed ID: 14598038
[TBL] [Abstract][Full Text] [Related]
14. [Not Available].
Mohammad M; Alaoui-Ismaili Z; Baandrup L; Barzanji AF
Ugeskr Laeger; 2023 May; 185(19):. PubMed ID: 37170738
[TBL] [Abstract][Full Text] [Related]
15. Case series profile of olanzapine post-injection delirium/sedation syndrome.
Seebaluck J; Downes MA; Brown J; Harris K; Isoardi KZ; Chan BS
Br J Clin Pharmacol; 2023 Feb; 89(2):903-907. PubMed ID: 36349832
[TBL] [Abstract][Full Text] [Related]
16. Postinjection Delirium/Sedation Syndrome After 31st Long-Acting Olanzapine Depot Injection.
Venkatesan V; Khanra S; Mandal K; Deepak MB
Clin Neuropharmacol; 2019; 42(2):64-65. PubMed ID: 30747749
[TBL] [Abstract][Full Text] [Related]
17. Comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized, open-label study in outpatients with schizophrenia.
Detke HC; Weiden PJ; Llorca PM; Choukour M; Watson SB; Brunner E; Ascher-Svanum H
J Clin Psychopharmacol; 2014 Aug; 34(4):426-34. PubMed ID: 24781441
[TBL] [Abstract][Full Text] [Related]
18. Follow-up study of patients treated with olanzapine pamoate in France in real-life treatment situation.
Chartier F; Rouillon F; Berggren L; Jamonneau I; Falissard B; Llorca PM
Encephale; 2017 Aug; 43(4):303-310. PubMed ID: 28709669
[TBL] [Abstract][Full Text] [Related]
19. A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection.
Atkins S; Detke HC; McDonnell DP; Case MG; Wang S
BMC Psychiatry; 2014 Jan; 14():7. PubMed ID: 24423017
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study.
McDonnell DP; Landry J; Detke HC
Int Clin Psychopharmacol; 2014 Nov; 29(6):322-31. PubMed ID: 24850228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]